ACTIVE

NORDIC PHARMA

Export PDF

Financial year 2025 · Closed on 31/12/2025

Net result387,2 k €+69,3 %over 1 year

Gross margin647,9 k €+17,3 %over 1 year

Equity232,8 k €+250,8 %over 1 year

Workforce1,3 ETP-27,8 %over 1 year

Identity

Source · BCE/KBO

NORDIC PHARMA is a Public limited company incorporated in 2007. Its main activity is: Market research and public opinion polling. Its registered office is in Antwerpen. It employs on average 1,3 ETP workers (FTE).

Legal situation: Normal situation
BCE/KBO no. / VAT: BE 0892.926.867
Incorporation: 19/10/2007
Legal form: Public limited company
Registered office: Uitbreidingstraat 84.3
2600 Antwerpen · FlandreSee on map
Contributed capital: 752 727,27 €
Latest accounts: 31/12/2025
Average workforce: 1,3 ETP

Activities (NACE)

73200Market research and public opinion polling· main 73200Market research and public opinion polling 74131Specialised design activities 72109Research and experimental development on natural sciences and engineering 72190Other research and experimental development on natural sciences and engineering 73100Advertising

Joint committees (2)

Signals

ProfitableLow riskGood liquidityPositive cashflowPositive EBITDAHealthy social debts

Financials

Source · NBB, 18 filings

Trend over 18 financial years

	2025		2024		2023		2022		2021
Income statement
Gross margin	647,9 k €	+17.3%	552,5 k €	+22.5%	451,1 k €	-6.9%	484,7 k €	+14.1%	424,9 k €
EBITDA	428,4 k €	+44.7%	296 k €	+161%	-485,3 k €	-692%	-61,2 k €	+57.2%	-143 k €
Operating result	428,4 k €	+57.6%	271,8 k €	+156%	-485,3 k €	-1032%	-42,9 k €	+74.4%	-167,5 k €
Net result	387,2 k €	+69.3%	228,7 k €	+144%	-523,3 k €	-909%	-51,9 k €	+70.5%	-176,1 k €
Balance sheet
Equity	232,8 k €	+251%	-154,4 k €	+59.7%	-383,1 k €	-373%	140,1 k €	-27.0%	192 k €
Total assets	1,3 M €	+16.7%	1,1 M €	-21.3%	1,4 M €	+34.5%	1,1 M €	+23.4%	872 k €
Cash	129,6 k €	-63.4%	354 k €	+27.0%	278,8 k €	+80.3%	154,6 k €	-29.5%	219,3 k €
Debts	1 M €	-8.1%	1,1 M €	-28.1%	1,6 M €	+93.1%	816,1 k €	+54.5%	528,4 k €
Other
Workforce	1,3 ETP	-27.8%	1,8 ETP	-43.8%	3,2 ETP	0.0%	3,2 ETP	-20.0%	4,0 ETP

Valuation

Indicative valuation

As an indication, this company is worth

between 250 k€ and 500 k€

See the valuation

Board of directors

Source · NBB, accounts to 31/12/2025

3 active · 16 ended

Active mandates

Anders LOFGREN

Managing director · since 01 juin 2023 · until 10 juin 2027

Active

Charlotte PHELPS

Director · since 01 juin 2023 · until 10 juin 2027

Active

Graham CLARK

Director · since 01 juin 2023 · until 10 juin 2027

Active

Ended mandates

Anders LÖFGREN

Director · since 11 juin 2021 · until 11 juin 2027

Ended

Enrique DE LA RUBIA

Director · since 11 juin 2021 · until 01 juin 2023

Ended

Enrique DE LA RUBIA

Director · since 11 juin 2021 · until 11 juin 2027

Ended

Thierry SEMPERE

Director · since 11 septembre 2019 · until 11 juin 2021

Ended

Full financial information

Source · NBB

	2025	2024	2023	2022	2021	2020
Type of account	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model
Start of the financial year	01/01/2025	01/01/2024	01/01/2023	01/01/2022	01/01/2021	01/01/2020
Closing of the financial year	31/12/2025	31/12/2024	31/12/2023	31/12/2022	31/12/2021	31/12/2020
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	08/07/2026	30/07/2025	24/07/2024	30/08/2023	09/08/2022	30/07/2021
General meeting	11/06/2026	12/06/2025	13/06/2024	08/06/2023	09/06/2022	10/06/2021
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for 7 days

Annual accounts filings

Source · NBB, 18 filings

Model	Closing	General meeting	Filed	Language	Document
Abridged model	31/12/2025	11/06/2026	08/07/2026	Dutch	PDF
Abridged model	31/12/2024	12/06/2025	30/07/2025	Dutch	PDF
Abridged model	31/12/2023	13/06/2024	24/07/2024	Dutch	PDF
Abridged model	31/12/2022	08/06/2023	30/08/2023	Dutch	PDF
Abridged model	31/12/2021	09/06/2022	09/08/2022	Dutch	PDF
Abridged model	31/12/2020	10/06/2021	30/07/2021	Dutch	PDF
Abridged model	31/12/2019	11/06/2020	27/08/2020	Dutch	PDF
Abridged model	31/12/2018	13/06/2019	05/07/2019	Dutch	PDF
Abridged model	31/12/2017	14/06/2018	29/08/2018	Dutch	PDF
Abridged model	31/12/2016	08/06/2017	08/08/2017	Dutch	PDF
Abridged model	31/12/2015	09/06/2016	02/08/2016	Dutch	PDF
Abridged model	31/12/2014	11/06/2015	27/07/2015	Dutch	PDF
Abridged model	31/12/2013	12/06/2014	23/07/2014	Dutch	PDF
Abridged model	31/12/2012	13/06/2013	23/08/2013	Dutch	PDF
Abridged model	31/12/2011	14/06/2012	22/06/2012	Dutch	PDF
Abridged model	31/12/2010	09/06/2011	27/07/2011	Dutch	PDF
Abridged model	31/12/2009	10/06/2010	10/06/2010	Dutch	PDF
Abridged model	31/12/2008	05/05/2009	15/06/2009	Dutch	PDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 250 k€ and 500 k€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2025

3 active · 16 ended

Active mandates

Anders LOFGREN

Managing director · since 01 juin 2023 · until 10 juin 2027

Active

Charlotte PHELPS

Director · since 01 juin 2023 · until 10 juin 2027

Active

Graham CLARK

Director · since 01 juin 2023 · until 10 juin 2027

Active

Ended mandates

Anders LÖFGREN

Director · since 11 juin 2021 · until 11 juin 2027

Ended

Enrique DE LA RUBIA

Director · since 11 juin 2021 · until 01 juin 2023

Ended

Enrique DE LA RUBIA

Director · since 11 juin 2021 · until 11 juin 2027

Ended

Thierry SEMPERE

Director · since 11 septembre 2019 · until 11 juin 2021

Ended

Ownership and network

Looking for more information about this company?

Try for 7 days

Belgian Official Gazette publications

Source · Belgian Official Gazette

Mandates12/01/2026
ONTSLAGEN - BENOEMINGEN
PDF
Mandates09/10/2025
ONTSLAGEN - BENOEMINGEN
PDF
Mandates25/08/2025
ONTSLAGEN - BENOEMINGEN
PDF
Mandates17/12/2024
ONTSLAGEN - BENOEMINGEN
PDF
Registered office25/01/2024
MAATSCHAPPELIJKE ZETEL
PDF
Mandates11/10/2023
ONTSLAGEN - BENOEMINGEN
PDF
Mandates10/05/2022
ONTSLAGEN - BENOEMINGEN
PDF
Mandates29/11/2019
ONTSLAGEN - BENOEMINGEN
PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

2025
Annual accounts 2025387,2 k €↑
2024
Annual accounts 2024228,7 k €↑
2023
Annual accounts 2023-523,3 k €↓
2022
Annual accounts 2022-51,9 k €↑
2021
Annual accounts 2021-176,1 k €↓
2020
Annual accounts 202012,4 k €↑
2019
Annual accounts 201910,9 k €↓
2018
Annual accounts 201838 k €↑
2017
Annual accounts 201735,9 k €↑
2016
Annual accounts 201622,6 k €↓
2015
Annual accounts 201528,2 k €↑
2014
Annual accounts 2014-603,3 k €↓
2013
Annual accounts 20138,9 k €↑
2012
Annual accounts 20127,5 k €↑
2011
Annual accounts 2011-52,8 k €↓
2010
Annual accounts 2010-23,7 k €↑
2009
Annual accounts 2009-327,3 k €↑
2008
Annual accounts 2008-513,2 k €
19/10/2007
IncorporationPublic limited company

NORDIC PHARMA

Overview

Identity

Financials

Valuation

Indicative valuation

Board of directors

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline

Timeline